![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, March 10, 2021 10:41:24 PM
EUA Debate
EUA's Debate!!
I have read some posts regarding EUA's and I thought I would clarify a few things points:I having been in the medical device space for 29 years and some of those years working closely with my regulatory colleagues to help them submit our FDA applications.
1) The FDA process for EUA's: Companies have to apply for the EUA. I have read comments like "the FDA rejected the EUA from CYDY". That is not the case. An 8K will be issued within the allowed window, that CYDY submitted an application for an EUA. This submission would be considered "material news" and CYDY has not revealed that yet!
2) FDA approvals and EUA's can be conditional. YES, in fact all approvals are at a minimum conditional because they involve labeling. The labeling contains the conditions/indications for use. Other conditional approvals or EUA's pre-specify exactly what conditions the FDA might impose. Many products get an approval and the condition is that the FDA still wants more data and requires the company to continue with a Post Market Study. The FDA has the ability to do that with Leronlimab, if CYDY could submit their CD12 data (Which FDA has already seen) and on CYDY's application. CYDY could state "we are requesting EUA for COVID Critical patients." The FDA could GRANT an EUA to CYDY for that indication with the condition that they also complete the CD16 140 patient trial.
On the conference call NP in his prepared remarks mentioned at the 5:52 time frame that an EUA could be submitted with CD12 data. But, we all know NP, later on during the Q&A session he was not as clear. In fact, he implied, an EUA submission for CD16 followed by the BLA and full approval.
3) EUA's and Full approval are different and they are not the same. However, they both allow the company to begin marketing/Selling the product under the conditions imposed in the EUA or Full Approval...and you should know that the FDA does not use the word "approval" they use the word "Clearance" . They "clear" a product for use, and then they name the indications/conditions.
Nonetheless, I hope that clarify's a couple of things regarding EUA's and I hope that TEAM CYDY feels that they could/should submit an application for an EUA using other data points that point towards COVID Critical patients.
Recent CYDY News
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM